DDInter478 DDInter1676
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Daratumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Daratumumab {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Daratumumab may lead to a major life threatening interaction when taken with Cladribine
Daratumumab may lead to a major life threatening interaction when taken with Rotavirus vaccine